WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 510298
CAS#: 550999-74-1 (HCl)
Description: Encenicline, also known as EVP-6124 and MT-4666, is a novel α7 nicotinic acetylcholine receptor agonist that enhances dopamine, acetylcholine, and glutamate efflux in rat cortex and nucleus accumbens. EVP-6124 improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors.
MedKoo Cat#: 510298
Name: Encenicline HCl salt
CAS#: 550999-74-1 (HCl)
Chemical Formula: C16H18Cl2N2OS
Exact Mass: 356.0517
Molecular Weight: 357.3
Elemental Analysis: C, 53.79; H, 5.08; Cl, 19.84; N, 7.84; O, 4.48; S, 8.97
Related CAS #: 550999-75-2
Synonym: EVP-6124; EVP 6124; EVP6124; MT-4666; MT4666; MT 4666; Encenicline HCl.
IUPAC/Chemical Name: (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride.
InChi Key: OIJYTJGIDVTCFF-ZOWNYOTGSA-N
InChi Code: InChI=1S/C16H17ClN2OS.ClH/c17-12-3-1-2-11-8-14(21-15(11)12)16(20)18-13-9-19-6-4-10(13)5-7-19;/h1-3,8,10,13H,4-7,9H2,(H,18,20);1H/t13-;/m0./s1
SMILES Code: O=C(C1=CC2=CC=CC(Cl)=C2S1)N[C@H]3CN4CCC3CC4.[H]Cl
Appearance: white to off-white solid powder
Purity: >95% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 357.3 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Pedersen CS, SÃ¸rensen DB, Parachikova AI, Plath N. PCP-induced deficits in murine nest building activity: Employment of an ethological rodent behavior to mimic negative-like symptoms of schizophrenia. Behav Brain Res. 2014 Jul 24. pii: S0166-4328(14)00472-0. doi: 10.1016/j.bbr.2014.07.023. [Epub ahead of print] PubMed PMID: 25064467.
2: Huang M, Felix AR, Flood DG, Bhuvaneswaran C, Hilt D, Koenig G, Meltzer HY. The novel α7 nicotinic acetylcholine receptor agonist EVP-6124 enhances dopamine, acetylcholine, and glutamate efflux in rat cortex and nucleus accumbens. Psychopharmacology (Berl). 2014 May 9. [Epub ahead of print] PubMed PMID: 24810107.
3: Preskorn SH. The role of proof of concept (POC) studies in drug development using the EVP-6124 POC study as an example. J Psychiatr Pract. 2014 Jan;20(1):59-60. doi: 10.1097/01.pra.0000442938.61575.c2. PubMed PMID: 24419310.
4: Preskorn SH, Gawryl M, Dgetluck N, Palfreyman M, Bauer LO, Hilt DC. Normalizing effects of EVP-6124, an alpha-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia. J Psychiatr Pract. 2014 Jan;20(1):12-24. doi: 10.1097/01.pra.0000442935.15833.c5. PubMed PMID: 24419307.
5: Citrome L. A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach. CNS Drugs. 2013 Nov;27(11):879-911. doi: 10.1007/s40263-013-0105-7. Review. PubMed PMID: 24062193.
6: Prickaerts J, van Goethem NP, Chesworth R, Shapiro G, Boess FG, Methfessel C, Reneerkens OA, Flood DG, Hilt D, Gawryl M, Bertrand S, Bertrand D, KÃ¶nig G. EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors. Neuropharmacology. 2012 Feb;62(2):1099-110. doi: 10.1016/j.neuropharm.2011.10.024. Epub 2011 Nov 10. PubMed PMID: 22085888.